<DOC>
	<DOC>NCT00195364</DOC>
	<brief_summary>The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU</brief_summary>
	<brief_title>Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>To have completed 0881A1301EU study in Spain Clinical diagnosis by ACR revised criteria of rheumatoid arthritis. Hypersensibility to etanercept or any of its components Significant concurrent medical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>